



Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

March 2, 2026

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya's Chief Executive Officer, will participate in a fireside chat on Monday, March 9, 2026, at 1:00 pm ET.

The live webcast of the fireside chat may be accessed from the Investors section of [Tenaya's website](#). An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya's pipeline includes clinical-stage candidates TN-201, a gene therapy for *MYBPC3*-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for *PKP2*-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Tenaya Contacts

Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors

Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com